Video

New Treatment Could Upend Standard of Care for Advanced Prostate Cancer

Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer, and how this drug could interrupt the typical standard of care. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.

Morris said the typical sequence for a patient with advanced prostate cancer would begin with a testosterone-lowering agent in combination with an androgen receptor pathway inhibitor or chemotherapy, followed by a treatment that they had not previously received. If it were to be approved in the future, Morris said 177Lu-PSMA-617 could represent a new option.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com